Table 1.
Summary of the clinical features and immunophenotype of mediastinal lymphomas (session 2)
| PMBL (N = 4) | Mediastinal “gray-zone” lymphoma (N = 7) | Composite lymphoma: CHL and DLBCL (N = 4) | ||
|---|---|---|---|---|
| Demographic information | ||||
| Age range | 21–48 | 25–85 | 22–54 | |
| Sex | 4F | 6 M, 1F | 4F | |
| Site | Mediastinal and/or cervical | Mediastinal and/or cervical, 1 inguinal | Mediastinal | |
| Immunohistologic markers | ||||
| CHL-like areas | PMBL-like areas | |||
| CD45 | 3/3 | 3/5 | 0/3 | 3/3 |
| CD20 | 4/4 | 6/7 | 2/4a | 4/4 |
| CD30 | 4/4 | 7/7 | 4/4 | 3/4 |
| CD15 | 0/4 | 4/7 | 4/4 | 0/4 |
| PAX5 | 3/3 | 4/7 | 3/3a | 3/3 |
| OCT-2 | 2/2 | 3/5 | 0/3 | 3/3 |
| CD23 | ND | 2/3 | 0/3 | 3/3 |
| MAL | 3/4 | 4/6 | 2/2 | 4/4 |
| EBV (EBER) | 0/4 | 1/6 | 4/4 | 4/4 |
PMBL primary mediastinal B cell lymphoma, CHL classical Hodgkin lymphoma, DLBCL diffuse large B cell lymphoma, EBV Epstein–Barr virus, ND not done
aWeak expression